Replimune Group (REPL) Stock Forecast & Price Target

Compare

471 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REPL Analyst Ratings

Moderate Buy

2 Buy

2 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Replimune

Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REPL Stock 12 Month Forecast

Average Price Target

$12.33

▲(76.19% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $12.33 with a high forecast of $14.00 and a low forecast of $11.00. The average price target represents a 76.19% change from the last price of $7.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","6":"$6","9":"$9","12":"$12","15":"$15"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.333333333333332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6,9,12,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.975,7.515384615384615,8.055769230769231,8.596153846153847,9.13653846153846,9.676923076923078,10.217307692307692,10.757692307692308,11.298076923076923,11.838461538461539,12.378846153846155,12.919230769230769,13.459615384615386,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.975,7.387179487179487,7.799358974358974,8.211538461538462,8.623717948717948,9.035897435897436,9.448076923076922,9.86025641025641,10.272435897435896,10.684615384615384,11.09679487179487,11.508974358974358,11.921153846153846,{"y":12.333333333333332,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.975,7.2846153846153845,7.594230769230769,7.903846153846153,8.213461538461537,8.523076923076923,8.832692307692307,9.142307692307693,9.451923076923077,9.76153846153846,10.071153846153846,10.38076923076923,10.690384615384616,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.975,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$12.33

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Allison Bratzel

Piper Sandler

$13→$14

Buy

100.00%

Upside

Reiterated

02/05/26

Replimune price target raised to $14 from $13 at Piper SandlerReplimune price target raised to $14 from $13 at Piper Sandler

Anupam Rama

J.P. Morgan

Hold

―

Reiterated

02/03/26

Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD)

Evan Seigerman

BMO Capital

$11

Hold

57.14%

Upside

Reiterated

01/14/26

Replimune Group (REPL) Receives a Hold from BMO Capital

Robert Burns

H.C. Wainwright

$12

Buy

71.43%

Upside

Reiterated

11/06/25

Positive Outlook for Replimune Group: Buy Rating Affirmed on Promising RP1 + Opdivo Therapy and Strong Financial Position

Jonathan Chang

Leerink Partners

$3→$13

Buy

85.71%

Upside

Upgraded

10/22/25

Replimune upgraded to Outperform from Market Perform at LeerinkReplimune upgraded to Outperform from Market Perform at Leerink

Peter Lawson

Barclays

Hold

-57.14%

Downside

Reiterated

10/21/25

Barclays Keeps Their Hold Rating on Replimune Group (REPL)

Robert Driscoll

Wedbush

$4→$18

Buy

157.14%

Upside

Upgraded

10/20/25

Replimune upgraded to Outperform from Neutral at WedbushReplimune upgraded to Outperform from Neutral at Wedbush

Roger Song

Jefferies

$10→$8

Buy

14.29%

Upside

Reiterated

08/11/25

Jefferies Keeps Their Buy Rating on Replimune Group (REPL)

Li Watsek

Cantor Fitzgerald

Buy

―

Upgraded

07/30/25

Replimune upgraded to Overweight from Neutral at Cantor FitzgeraldReplimune upgraded to Overweight from Neutral at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Allison Bratzel

Piper Sandler

$13→$14

Buy

100.00%

Upside

Reiterated

02/05/26

Replimune price target raised to $14 from $13 at Piper SandlerReplimune price target raised to $14 from $13 at Piper Sandler

Anupam Rama

J.P. Morgan

Hold

―

Reiterated

02/03/26

Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD)

Evan Seigerman

BMO Capital

$11

Hold

57.14%

Upside

Reiterated

01/14/26

Replimune Group (REPL) Receives a Hold from BMO Capital

Robert Burns

H.C. Wainwright

$12

Buy

71.43%

Upside

Reiterated

11/06/25

Positive Outlook for Replimune Group: Buy Rating Affirmed on Promising RP1 + Opdivo Therapy and Strong Financial Position

Jonathan Chang

Leerink Partners

$3→$13

Buy

85.71%

Upside

Upgraded

10/22/25

Replimune upgraded to Outperform from Market Perform at LeerinkReplimune upgraded to Outperform from Market Perform at Leerink

Peter Lawson

Barclays

Hold

-57.14%

Downside

Reiterated

10/21/25

Barclays Keeps Their Hold Rating on Replimune Group (REPL)

Robert Driscoll

Wedbush

$4→$18

Buy

157.14%

Upside

Upgraded

10/20/25

Replimune upgraded to Outperform from Neutral at WedbushReplimune upgraded to Outperform from Neutral at Wedbush

Roger Song

Jefferies

$10→$8

Buy

14.29%

Upside

Reiterated

08/11/25

Jefferies Keeps Their Buy Rating on Replimune Group (REPL)

Li Watsek

Cantor Fitzgerald

Buy

―

Upgraded

07/30/25

Replimune upgraded to Overweight from Neutral at Cantor FitzgeraldReplimune upgraded to Overweight from Neutral at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Replimune Group

3 Months

xxx

Success Rate

7/15 ratings generated profit

Average Return

-3.76%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of -3.76% per trade.

1 Year

Robert DriscollWedbush

Success Rate

6/15 ratings generated profit

Average Return

-0.60%

a rating ―

Copying Robert Driscoll's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -0.60% per trade.

2 Years

xxx

Success Rate

2/15 ratings generated profit

Average Return

-29.94%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 13.33% of your transactions generating a profit, with an average return of -29.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REPL Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REPL has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. REPL average Analyst price target in the past 3 months is 12.33.

Each month's total comprises the sum of three months' worth of ratings.

REPL Financial Forecast

REPL Earnings Forecast

Next quarter’s earnings estimate for REPL is -$0.74 with a range of -$0.95 to -$0.52. The previous quarter’s EPS was -$0.77. REPL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year REPL has Performed in-line its overall industry.

No data currently available

REPL Sales Forecast

Next quarter’s sales forecast for REPL is $813.00K with a range of $0.00 to $5.69M. The previous quarter’s sales results were $0.00. REPL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year REPL has Performed in-line its overall industry.

REPL Stock Forecast FAQ

What is REPL’s average 12-month price target, according to analysts?

Based on analyst ratings, Replimune Group Inc’s 12-month average price target is 12.33.

What is REPL’s upside potential, based on the analysts’ average price target?

Replimune Group Inc has 76.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REPL a Buy, Sell or Hold?

Replimune Group Inc has a consensus rating of Moderate Buy which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.

What is Replimune Group Inc’s price target?

The average price target for Replimune Group Inc is 12.33. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $11.00. The average price target represents 76.19% Increase from the current price of $7.

What do analysts say about Replimune Group Inc?

Replimune Group Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of REPL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Replimune Group (REPL) Stock Forecast & Price Target

REPL Analyst Ratings

REPL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Replimune Group

REPL Analyst Recommendation Trends

REPL Financial Forecast

REPL Earnings Forecast

REPL Sales Forecast

REPL Stock Forecast FAQ

Detailed List of Analyst Forecasts